Background/Aims: Transforming growth factor (TGF) β is strongly implicated in the progression of renal fibrosis. TGFβ1 is reported to cause epithelial-mesenchymal transition, inhibition of epithelial cell proliferation, increased apoptosis, auto-induction of TGFβ production and induction of secondary mediators of tissue fibrosis such as connective tissue growth factor (CTGF, CCN2). The aims of this study were to investigate the role of the Ras/MAP kinase pathway in TGFβ1 inhibition of proliferation, TGFβ auto-induction and TGFβ1-induced CTGF expression in HKC human renal tubule epithelial cells. Methods and Results: TGFβ1 (0–25 ng/ml) inhibited proliferation of HKC cells and at 25 ng/ml also induced apoptosis. After 5–10 min of incubation, TGFβ1 increased cellular levels of phospho-ERK1/2 and phospho-AKT with a bell-shaped dose-response curve with a maximally effective concentration of 2.5 ng/ml. TGFβ3 caused an increase in extracellular TGFβ1, which was significantly reduced in the presence of PD 98059. TGFβ1 increased cellular and secreted CTGF protein in HKC cells in a MEK-dependent manner. To identify the Ras isoform involved, specific antisense oligonucleotides targeted to Ha-Ras, Ki-Ras and N-Ras were employed. Only inhibition of N-Ras resulted in a significant reduction of auto-induced TGFβ1 secretion and TGFβ1-induced cellular and secreted CTGF. Conclusion: These results establish that the Ras/MAP kinase pathway, specifically through N-Ras, mediates TGFβ1 auto-induction and TGFβ1-induced CTGF expression in human renal tubule epithelial cells.

Keywords:
Transforming growth factor β, Renal fibrosis, Ras/MAP kinase pathway, Renal tubule epithelial cells
1.
Wells RG: Fibrogenesis. V. TGF-beta signaling pathways. Am J Physiol Gastrointest Liver Physiol 2000;279:G845–G850.
2.
Diamond JR, Kees-Folts D, Ding G, Frye JE, Restrepo NC: Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis. Am J Physiol 1994;266:F926–F933.
3.
Fukuda K, Yoshimoto K, Yanagida T, Tokumoto M, Hirakata H: Quantification of TGF-beta1 mRNA along rat nephron in obstructive nephropathy. Am J Physiol Renal Physiol 2001;281:F513–F521.
4.
Basile DP, Martin DR, Mammerman MR: Extracellular matrix-related genes in kidney after ischemic injury: potential role for TGF-beta in repair. Am J Physiol Renal Physiol 1998;275:F894–F903.
5.
Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN: Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int 1992;41:107–114.
6.
Schuster N, Krieglstein K: Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res 2002;307:1–14.
7.
Han DC, Isono M, Hoffman BB, Ziyadeh FN: High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: mediation by autocrine activation of TGF-beta. J Am Soc Nephrol 1999;10:1891–1899.
8.
Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E: TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996;10:2462–2477.
9.
Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M, Sugaya T, Kopp JB, Suzuki H, Kikuta T: Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005;16:133–143.
10.
Mulder KM, Morris SL: Activation of p21ras by transforming growth factor beta in epithelial cells. J Biol Chem 1992;267:5029–5031.
11.
Yan Z, Winawer S, Friedman E: Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J Biol Chem 1994;269:231–237.
12.
Hartsough MT, Frey RS, Zipfel PA, Buard A, Cook SJ, McCormick F, Mulder KM: Altered transforming growth factor signalling in epithelial cells when ras activation is blocked. J Biol Chem 1996;271:22368–22375.
13.
Yue J, Mulder KM: Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. J Biol Chem 2000;275:30765–30773.
14.
Phanish MK, Wahab NA, Hendry BM, Dockrell ME: TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron Exp Nephrol 2005;100:156–165.
15.
Moon A, Kim MS, Kim TG, Kim SH, Kim HE, Chen YQ, Kim HR: H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer 2000;85:176–181.
16.
Carbone A, Gusella GL, Radzioch D, Varesio L: Human Harvey-ras is biochemically different from Kirsten- or N-ras. Oncogene 1991;6:731–737.
17.
Niv H, Gutman O, Kloog Y, Henis YI: Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of liver cells. J Cell Biol 2002;157:865–872.
18.
Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489–27494.
19.
Sharpe CC, Dockrell ME, Noor MI, Monia BP, Hendry BM: Role of Ras isoforms in the stimulated proliferation of human renal fibroblasts in primary culture. J Am Soc Nephrol 2000;11:1600–1606.
20.
Fraser D, Wakefield L, Phillips A: Independent regulation of transforming growth factor-beta1 transcription and translation by glucose and platelet-derived growth factor. Am J Pathol 2002;161:1039–1049.
21.
Yue J, Buard A, Mulder KM: Blockade of TGFbeta3 up-regulation of p27Kip1 and p21Cip1 by expression of RasN17 in epithelial cells. Oncogene 1998;17:47–55.
22.
Yamamoto H, Atsuchi N, Tanaka H, Ogawa W, Abe M, Takeshita A, Ueno H: Separate roles for H-Ras and Rac in signalling by transforming growth factor (TGF)-beta. H-Ras is essential for activation of MAP kinase, partially required for transcriptional activation by TGF-beta, but not required for signalling of growth suppression by TGF-beta. Eur J Biochem 1999;264:110–119.
23.
Mulder KM: Role of Ras and Mapks in TGFbeta signalling. Cytokine Growth Factor Rev 2000;11:23–35.
24.
Grande JP, Warner GM, Walker HJ, Yusufi ANK, Cheng J, Gray CE, Kopp JB, Nath KA: TGF-beta1 is an autocrine mediator of renal tubular epithelial cell growth and collagen IV production. Exp Biol Med 2002;227:171–181.
25.
Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB: Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 1990;10:1492–1497.
26.
Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR: Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996;107:404–411.
27.
Chen Y, Blom I, Sa S, Goldschmeding R, Abraham DJ, Leask A: CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int 2002;62:1149–1159.
28.
Leon J, Guerrero I, Pellicer A: Differential expression of the ras gene family in mice. Mol Cell Biol 1987;7:1535–1540.
29.
Maher J, Baker DA, Manning M, Dibb NJ, Roberts IA: Evidence for cell-specific differences in transformation by N-, H- and K-ras. Oncogene 1995;11:1639–1647.
30.
Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, Bronson RT, Umanoff H, Edelmann W, Kucherlapati R, Jacks T: K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 1997;11:2468–2481.
31.
Umanoff H, Edelmann W, Pellicer A, Kucherlapati R: The murine N-ras gene is not essential for growth and development. Proc Natl Acad Sci USA 1995;92:1709–1713.
32.
Jones MK, Jackson JH: Ras-GRF activates Ha-Ras, but not N-Ras or K-Ras 4B, protein in vivo. J Biol Chem 1998;273:1782–1787.
33.
Clyde-Smith J, Silins G, Gartside M, Grimmond S, Etheridge M, Apolloni A, Hayward N, Hancock JF: Characterization of RasGRP2, a plasma membrane-targeted, dual specificity Ras/Rap exchange factor. J Biol Chem 2000;275:32260–32267.
34.
Prior IA, Harding A, Yan J, Sluimer J, Parton RG, Hancock JF: GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nat Cell Biol 2001;3:368–375.
35.
Matallanas D, Arozarena I, Berciano MT, Aaronson DS, Pellicer A, Lafarga M, Crespo P: Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J Biol Chem 2003;178:4572–4581.
36.
Kranenburg O, Verlaan I, Moolenaar WH: Regulating c-Ras function. Cholesterol depletion affects caveolin association, GTP loading, and signaling. Curr Biol 2001;11:1880–1884.
37.
Razani B, Zhang XL, Bitzer M, von Gersdorff G, Bottinger EP, Lisanti MP: Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signalling through an interaction with the TGF-beta type I receptor. J Biol Chem 2001;276:6727–6738.
38.
Rebollo A, Martinez AC: Ras proteins: recent advances and new functions. Blood 1999;94:2971–2980.
39.
Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A: Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003;101:3126–3135.
40.
Darley RL, Pearn L, Omidvar N, Sweeney H, Fisher J, Phillips S, Hoy T, Burnett AK: Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood 2002; 100:4185–4192.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.